FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average I	burden
haiira nar raananaa	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response	s)														
1. Name and Address of Reporting Person* SHERWIN STEPHEN A			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director						
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.			3. Date of Earliest Transaction (Month/Day/Year) 05/15/2013							Officer (give	e title below)	Other	(specify below)			
SOUTH	SAN FRA	(Street) NCISCO, CA 94		4. If Ame	endmen	, Date	Origi	inal Filed(M	onth/Day/Year)		_X_1	Form filed by	One Reporting	p Filing(Check A Person Reporting Person	pplicable Line)	
(Cit	y)	(State)	(Zip)			Ta	ble I -	- Non-Deri	vative Secu	rities A	Acquired,	, Disposed	of, or Bene	ficially Owned	1	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			any	on Date, if		(Instr. 8)		4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)					d O Fo	wnership orm: Be irect (D) Ov	Nature Indirect eneficial wnership astr. 4)	
							Code	e V A	mount (A)		Price			(I	nstr. 4)	
								in this f	orm are n	ot req	quired to	respond	unless the	tion containe e form	d SEC 14	74 (9-02)
			Table II -					in this f	orm are no s a curren	ot req tly va Benefic	quired to alid OMB cially Ow	respond control n	unless the		d SEC 14'	74 (9-02)
Security	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transac Code	ts, calls 5. tion of Se or of (Ir	warr Numb	er ntive s l (A) sed	in this to display nired, Disposoro options, co	orm are not a corrent of the correct	Benefic curitie	quired to alid OMB cially Ow	respond control n ned	unless the umber.		10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	ts, calls 5. tion of Se) Ac or of (Ir an	Number Derivative quired Dispose (D) str. 3,	er ntive s l (A) ssed 4,	in this to display tired, Dispositions, conficulty of the Exercise Expiration 1	s a curren sed of, or E nvertible se recisable and Date y/Year) Expiration	Senefic Courities 7. 01 Si (I	quired to alid OMB cially Owners. T. Title and of Underly Securities	respond control n ned	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia Ownersh

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
SHERWIN STEPHEN A C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ Dolly Vance (Attorney-In-Fact)	05/28/2013
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.